Mitochondrial Diseases

1. Clinical Overview

Summary

Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by defects in oxidative phosphorylation (OXPHOS), the final common pathway of aerobic energy metabolism. They represent one of the most common groups of inherited metabolic disorders, affecting approximately 1 in 4,300 individuals. [1,2]

These conditions arise from mutations in either mitochondrial DNA (mtDNA) genes (showing maternal inheritance) or nuclear DNA (nDNA) genes (showing Mendelian inheritance patterns). Because mitochondria are present in virtually all cells and tissues have variable energy requirements, mitochondrial diseases exhibit remarkable phenotypic heterogeneity—the same genetic defect can produce different clinical syndromes, and different mutations can produce similar phenotypes. [1,3]

The hallmark of mitochondrial disease is multisystem involvement, typically affecting high-energy-demanding organs: central nervous system (stroke-like episodes, seizures, dementia, ataxia), skeletal muscle (myopathy, exercise intolerance, ptosis, ophthalmoplegia), eye (optic atrophy, retinopathy), heart (cardiomyopathy, conduction defects), and endocrine system (diabetes mellitus, short stature). [1,4]

Classic mitochondrial syndromes include MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), MERRF (Myoclonic Epilepsy with Ragged Red Fibers), Kearns-Sayre Syndrome, Leigh Syndrome, and Leber Hereditary Optic Neuropathy (LHON). [1]

Diagnosis relies on clinical suspicion combined with biochemical testing (elevated lactate), neuroimaging (characteristic MRI patterns), muscle biopsy histology (ragged red fibers), and genetic testing. Currently, treatment remains largely supportive, though disease-modifying therapies are emerging and mitochondrial replacement therapy offers preventive strategies for maternal transmission. [5,6]

Key Facts

• Prevalence: 1 in 4,300 for clinically manifest disease; carrier frequency for pathogenic mtDNA mutations estimated at 1 in 200. [2]
• Genetics:
  • "mtDNA mutations: Maternal inheritance, heteroplasmy (mixture of mutant and wild-type mtDNA), threshold effect."
  • "nDNA mutations: Autosomal recessive, autosomal dominant, or X-linked inheritance patterns."
• Age of Onset: Any age—from neonatal period to late adulthood, correlating with mutation type and heteroplasmy level.
• Clinical Rule: "Any symptom, any organ, any age"—mitochondrial disease should be considered in unexplained multisystem disorders.
• Biochemical Hallmark: Elevated lactate (blood and CSF) with elevated lactate-to-pyruvate ratio.
• Pathological Hallmark: Ragged red fibers on Gomori trichrome stain, cytochrome c oxidase (COX)-deficient fibers.
• Prognosis: Highly variable, from severe neonatal presentations incompatible with prolonged survival to mild adult-onset presentations with near-normal life expectancy.

Clinical Pearls

"The Stroke that Isn't a Stroke": In MELAS, patients experience stroke-like episodes that do NOT respect vascular territories. These represent focal metabolic crises rather than ischemic events, and thrombolysis is contraindicated. MRI shows cortical involvement (often posterior) with restricted diffusion that evolves atypically. [7]

"Diabetes and Deafness": The combination of diabetes mellitus and sensorineural deafness, especially in a lean individual with maternal family history, should immediately suggest mitochondrial disease (MIDD - Maternally Inherited Diabetes and Deafness, typically m.3243A>G mutation). [8]

"The Heteroplasmy Threshold": A mother with 10% mutant mtDNA may be asymptomatic, but the mitochondrial bottleneck during oogenesis means she can transmit 80% mutant load to offspring, resulting in severe disease. Phenotype depends critically on mutant load in affected tissues. [9]

"Ptosis + Ophthalmoplegia = Check the Heart": Chronic progressive external ophthalmoplegia (CPEO) warrants cardiac evaluation with ECG and echocardiography. Kearns-Sayre syndrome patients develop progressive AV block and require pacemaker implantation—this can be life-saving. [10]

"Avoid Valproate": Sodium valproate is contraindicated in mitochondrial disease due to its inhibition of β-oxidation and mitochondrial toxicity, which can precipitate acute hepatic failure and metabolic decompensation. [11]

---

2. Epidemiology

Prevalence and Incidence

Mitochondrial diseases are among the most common inherited metabolic disorders:

• Clinically Manifest Disease: Minimum prevalence of 1 in 4,300 adults. [2]
• Pathogenic mtDNA Mutations: Carrier frequency estimated at 1 in 200 individuals, though most carriers remain asymptomatic due to low heteroplasmy levels. [2]
• Specific Mutations:
  • m.3243A>G (most common pathogenic mtDNA variant): prevalence approximately 1 in 400.
  • "Common LHON mutations (m.11778G>A, m.14484T>C, m.3460G>A): combined prevalence approximately 1 in 30,000-50,000."

These figures likely underestimate true prevalence, as mitochondrial diseases remain underdiagnosed due to phenotypic heterogeneity and diagnostic challenges. [1,2]

Age Distribution

• Neonatal/Early Infantile: Severe presentations (e.g., Leigh syndrome) often manifest in first year of life.
• Childhood/Adolescence: MELAS, MERRF, Kearns-Sayre syndrome typically present between ages 5-20 years.
• Young Adult: LHON typically affects males aged 15-35 years.
• Adult-Onset: CPEO, mitochondrial myopathy, and late-onset presentations can occur in fourth to sixth decades.

Sex Distribution

• Most mitochondrial diseases affect males and females equally (maternal inheritance affects all offspring).
• LHON shows marked male predominance (60-90% of symptomatic patients are male), likely due to protective hormonal effects in females. [12]

Geographic Variation

Founder effects create regional hotspots:

• m.3243A>G particularly common in Northern European populations.
• LHON mutations show increased prevalence in certain populations (e.g., Finland, Northeast England).
• Specific mtDNA haplogroups modify disease expression and penetrance. [1]

---

3. Pathophysiology

Mitochondrial Structure and Function

The Powerhouse of the Cell

Mitochondria are double-membrane-bound organelles present in virtually all nucleated cells, responsible for generating cellular ATP through oxidative phosphorylation. Each cell contains hundreds to thousands of mitochondria, with tissue distribution reflecting energy demands. [13]

Key Structural Features:

• Outer membrane: Permeable to small molecules.
• Inner membrane: Highly folded (cristae), contains the electron transport chain (ETC) complexes.
• Matrix: Contains mitochondrial DNA, ribosomes, and enzymes for the Krebs cycle and β-oxidation.
• Intermembrane space: Site of proton accumulation driving ATP synthesis.

Mitochondrial DNA

Human mtDNA is a 16.6 kb circular, double-stranded molecule encoding:

• 13 polypeptides: All components of the OXPHOS system (7 of Complex I, 1 of Complex III, 3 of Complex IV, 2 of Complex V).
• 22 transfer RNAs (tRNAs): Required for mitochondrial protein synthesis.
• 2 ribosomal RNAs (rRNAs): Components of mitochondrial ribosomes.

Notably, Complex II is entirely nuclear-encoded, explaining why some presentations spare this complex. [1,13]

Additional approximately 1,500 nuclear genes encode mitochondrial proteins involved in OXPHOS assembly, mtDNA maintenance, mitochondrial dynamics, and other functions. [1]

The Electron Transport Chain and Oxidative Phosphorylation

The Proton Pump System

The ETC consists of five multi-subunit enzyme complexes embedded in the inner mitochondrial membrane:

Complex I (NADH:ubiquinone oxidoreductase):

• Largest complex: 45 subunits (7 mtDNA-encoded, 38 nDNA-encoded).
• Accepts electrons from NADH (generated by Krebs cycle, β-oxidation).
• Transfers electrons to ubiquinone (Coenzyme Q10).
• Pumps 4 protons from matrix to intermembrane space.
• Most common site of OXPHOS defects.

Complex II (Succinate dehydrogenase):

• Four subunits, all nDNA-encoded.
• Connects Krebs cycle directly to ETC.
• Transfers electrons from FADH₂ to ubiquinone.
• Does NOT pump protons (does not contribute to proton gradient).

Coenzyme Q10 (Ubiquinone):

• Lipid-soluble electron carrier.
• Shuttles electrons from Complexes I and II to Complex III.
• Reduction to ubiquinol (CoQ10H₂) carries electrons.

Complex III (Ubiquinol:cytochrome c oxidoreductase):

• 11 subunits (1 mtDNA-encoded).
• Transfers electrons from ubiquinol to cytochrome c.
• Pumps 4 protons per ubiquinol oxidized.

Cytochrome c:

• Small heme protein in intermembrane space.
• Shuttles electrons from Complex III to Complex IV.

Complex IV (Cytochrome c oxidase, COX):

• 13 subunits (3 mtDNA-encoded).
• Catalyzes reduction of oxygen to water (final electron acceptor).
• Pumps 2 protons per electron pair.
• Deficiency results in "COX-negative fibers" on histochemistry.

Complex V (ATP synthase):

• 16 subunits (2 mtDNA-encoded).
• Harnesses proton gradient (proton-motive force) to phosphorylate ADP to ATP.
• Rotary motor mechanism: F₀ component spans membrane, F₁ component synthesizes ATP. [13,14]

Chemiosmotic Coupling

The Mitchell hypothesis (Nobel Prize 1978): ETC creates an electrochemical gradient (approximately -180 mV membrane potential, pH gradient of ~1 unit) across the inner membrane. This proton-motive force drives ATP synthase, generating approximately 30-36 ATP molecules per glucose molecule oxidized. [14]

Mechanisms of Disease

1. Energy Failure (Primary Defect)

OXPHOS defects reduce ATP production, creating bioenergetic crisis in high-energy tissues:

• CNS: Neurons require constant ATP for ion pumps (Na⁺/K⁺-ATPase), neurotransmitter synthesis/release, axonal transport. Deficiency causes seizures, stroke-like episodes, dementia, ataxia.
• Skeletal Muscle: Muscle contraction consumes massive ATP. Deficiency causes weakness, exercise intolerance, myopathy.
• Cardiac Muscle: Heart has highest mitochondrial density (35% of cardiomyocyte volume). Deficiency causes cardiomyopathy, conduction defects.
• Retina/Optic Nerve: High metabolic demands. Deficiency causes vision loss, retinopathy.
• Cochlea: Hair cells require high ATP. Deficiency causes sensorineural deafness.
• Pancreatic β-cells: Insulin secretion is ATP-dependent. Deficiency causes diabetes mellitus. [1,13]

2. Lactic Acidosis (Secondary Consequence)

ATP deficiency triggers compensatory mechanisms:

• Upregulation of glycolysis: Cells attempt to generate ATP anaerobically.
• Pyruvate accumulates: Cannot be efficiently oxidized by defective mitochondria.
• Lactate accumulation: Pyruvate is reduced to lactate by lactate dehydrogenase.
• Elevated lactate/pyruvate ratio: Reflects NADH/NAD⁺ redox imbalance (typically > 20, normal less than 10).

Lactic acidosis can be chronic (mild elevation) or acute (metabolic crises precipitated by illness, fasting, exercise). [1,15]

3. Reactive Oxygen Species (ROS) Production

Defective ETC complexes "leak" electrons, generating superoxide radicals (O₂⁻):

• Normally, approximately 1-2% of oxygen consumed produces ROS.
• In OXPHOS defects, ROS production increases substantially.
• Oxidative damage: Lipid peroxidation, protein oxidation, DNA damage (including further mtDNA mutations—vicious cycle).
• Cell death: Apoptosis and necrosis in affected tissues. [13]

4. Impaired Calcium Homeostasis

Mitochondria regulate cytosolic Ca²⁺ levels:

• Matrix Ca²⁺ uptake requires membrane potential.
• OXPHOS defects impair Ca²⁺ buffering.
• Calcium dysregulation triggers excitotoxicity (CNS), impaired muscle relaxation, arrhythmias (heart). [13]

5. Mitochondrial Proliferation (Compensatory Response)

Cells respond to ATP deficit by:

• Increasing mitochondrial biogenesis: PGC-1α activation.
• Mitochondrial accumulation: Particularly subsarcolemmal regions in muscle.
• Pathological appearance: "Ragged red fibers" on Gomori trichrome stain—irregular accumulations of abnormal mitochondria appear as red-staining peripheral zones. [16]

Genetics: Unique Concepts in Mitochondrial Inheritance

1. Maternal Inheritance (mtDNA Mutations)

Mechanism:

• Oocytes contain approximately 100,000 mtDNA copies; sperm contribute approximately 100 copies.
• Sperm mitochondria are actively degraded after fertilization (ubiquitin-mediated autophagy).
• Result: All mtDNA is maternally inherited. [9]

Clinical Implications:

• Affected mothers transmit mutations to ALL offspring (sons and daughters equally).
• Affected fathers transmit to ZERO offspring.
• Maternal family history shows transmission through female lineage.

Exceptions:

• Extremely rare cases of paternal inheritance reported in literature.
• De novo mtDNA mutations occur (particularly large deletions in Kearns-Sayre syndrome). [9]

2. Heteroplasmy

Definition: Mixture of mutant and wild-type mtDNA within a cell, tissue, or individual.

Mechanism:

• Each cell contains hundreds to thousands of mtDNA molecules.
• Mutation can affect some molecules while others remain normal.
• Heteroplasmy level: Percentage of mutant mtDNA (e.g., 30% mutant, 70% wild-type).

Contrast with Homoplasmy:

• Homoplasmy: 100% mutant or 100% wild-type.
• Some mtDNA variants (e.g., LHON mutations) often present as homoplasmic. [9]

Clinical Significance:

• Heteroplasmy level determines phenotype severity.
• Levels can vary between tissues (tissue-specific heteroplasmy).
• Levels can change over time (generally increase with age in some mutations). [17]

3. Threshold Effect

Concept: Clinical manifestations appear when mutant load exceeds a critical threshold in affected tissue.

Typical Thresholds:

• 60-70% mutant mtDNA: Mild symptoms may emerge.
• 80-90% mutant mtDNA: Severe symptoms typically manifest.
• Thresholds vary by tissue (CNS has lower threshold than muscle).
• Thresholds vary by mutation. [9,17]

Clinical Implications:

• Individuals with same mutation but different heteroplasmy show different severity.
• Progressive increase in heteroplasmy can cause symptom progression.
• Explains incomplete penetrance in families.

4. Mitotic Segregation

Mechanism:

• During cell division, mitochondria (and mtDNA) are randomly distributed to daughter cells.
• Over multiple divisions, heteroplasmy levels can drift higher or lower (random genetic drift).

Clinical Implications:

• Different tissues develop different heteroplasmy levels.
• Explains variable organ involvement within same individual.
• Blood heteroplasmy may not reflect brain or muscle levels (complicates genetic testing). [9]

5. Mitochondrial Bottleneck

Concept: During oogenesis, mtDNA copy number transiently decreases to approximately 200 molecules before amplification to 100,000 in mature oocyte.

Consequences:

• Sampling effect: Random selection of mtDNA subset during bottleneck.
• Wide variance in offspring heteroplasmy: Mother with 30% mutant can produce offspring ranging from 5% to 90% mutant.
• Explains unpredictability of transmission.
• Reproductive counseling challenges. [9,18]

6. Nuclear DNA Mutations

Approximately 1,500 nuclear genes encode mitochondrial proteins:

Autosomal Recessive:

• Most common pattern for nDNA mitochondrial disease.
• Examples: SURF1 (Leigh syndrome), POLG (mitochondrial DNA depletion/deletion syndromes), TK2 (myopathic mtDNA depletion).
• Consanguinity increases risk.

Autosomal Dominant:

• Examples: OPA1 (dominant optic atrophy), POLG mutations (progressive external ophthalmoplegia, ataxia).
• Variable penetrance common.

X-linked:

• Example: PDHA1 (pyruvate dehydrogenase deficiency—affects males).
• Females may be mildly affected (X-inactivation). [1,3]

---

4. Clinical Syndromes: The "Big 5" and Beyond

1. MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes)

Genetics

• Most Common Mutation: m.3243A>G in MT-TL1 gene (tRNA-Leucine), accounts for approximately 80% of cases.
• Other mutations: m.3271T>C, m.3252A>G, m.13513G>A (less common).
• Maternal inheritance pattern. [7,19]

Clinical Features

Stroke-Like Episodes (defining feature):

• Occur in children/young adults (typical onset age 5-15 years).
• Recurrent episodes of acute focal neurological deficits.
• Do NOT respect vascular territories (differentiates from ischemic stroke).
• Cortical involvement: visual field defects, aphasia, hemiparesis, cortical blindness.
• Often preceded by migraines, vomiting, seizures.
• Posterior regions (occipital, parietal) preferentially affected. [7]

Neurological:

• Seizures (focal and generalized).
• Migraine-like headaches (often severe, with visual aura).
• Cognitive decline/dementia (progressive).
• Hearing loss (sensorineural).
• Ataxia, myoclonus (less prominent than MERRF).

Endocrine:

• Diabetes mellitus and deafness (MIDD presentation when m.3243A>G).
• Short stature (growth hormone deficiency).

Cardiac:

• Cardiomyopathy (hypertrophic or dilated).
• Wolff-Parkinson-White syndrome (pre-excitation).

Muscular:

• Exercise intolerance.
• Proximal myopathy (variable severity). [7,19]

Investigations

• Lactate: Elevated in blood and CSF (particularly during acute episodes).
• MRI Brain: T2/FLAIR hyperintensity in cortical gray matter (often posterior), does NOT conform to vascular territories. DWI shows restricted diffusion (cytotoxic edema). MR spectroscopy shows lactate peak.
• Muscle Biopsy: Ragged red fibers, COX-negative fibers, subsarcolemmal mitochondrial accumulation.
• Genetic Testing: Blood or urine sediment cells for m.3243A>G (muscle biopsy may be needed if blood negative).

Management

• Acute Stroke-Like Episode:
  • "L-Arginine: 500 mg/kg IV bolus over 30-60 minutes, then infusion (100-200 mg/kg/day). Nitric oxide donor improves cerebral perfusion. [20]"
  • Seizure control (avoid valproate).
  • Supportive care (hydration, treat infections).
• Chronic Prophylaxis:
  • Oral L-arginine (150-300 mg/kg/day) and/or L-citrulline.
  • Coenzyme Q10 (ubiquinone 300-600 mg/day).
• Monitoring: Annual cardiac echo and ECG, audiology, endocrine screening (diabetes), ophthalmology.
• Avoid: Valproate, prolonged fasting, excessive exercise.

Prognosis

• Highly variable, correlates with heteroplasmy level.
• Recurrent strokes cause cumulative neurological damage.
• Life expectancy often reduced (median survival 30-40 years in severe cases). [7,19]

---

2. MERRF (Myoclonic Epilepsy with Ragged Red Fibers)

Genetics

• Most Common Mutation: m.8344A>G in MT-TK gene (tRNA-Lysine), accounts for approximately 80% of cases.
• Other mutations: m.8356T>C, m.8363G>A.
• Maternal inheritance. [21]

Clinical Features

Core Tetrad:

1. Myoclonus: Action and stimulus-sensitive myoclonic jerks (hallmark feature).
2. Epilepsy: Generalized tonic-clonic seizures, often difficult to control.
3. Ataxia: Cerebellar ataxia (gait instability, limb incoordination).
4. Ragged Red Fibers: On muscle biopsy.

Additional Features:

• Sensorineural deafness (common).
• Dementia (progressive cognitive decline).
• Myopathy (proximal weakness, exercise intolerance).
• Peripheral neuropathy.
• Optic atrophy.
• Short stature.
• Lipomas (multiple symmetric lipomatosis occasionally reported). [21]

Onset

• Childhood to early adulthood (typical age 5-25 years).
• Progressive course.

Investigations

• Lactate: Elevated (blood and CSF).
• EEG: Generalized spike-wave discharges, photosensitivity.
• MRI Brain: Cerebellar atrophy, basal ganglia calcification.
• Muscle Biopsy: Abundant ragged red fibers, COX-negative fibers.
• Genetic Testing: m.8344A>G in blood (often high heteroplasmy).

Management

• Seizure Control: Levetiracetam, lamotrigine, benzodiazepines (for myoclonus). Avoid valproate.
• Myoclonus: Piracetam, clonazepam may provide symptomatic benefit.
• Supportive: CoQ10, multivitamins, physical therapy.
• Monitoring: Cardiac assessment (cardiomyopathy risk).

Prognosis

• Progressive neurological decline.
• Wheelchair dependency common by third or fourth decade.
• Variable life expectancy (correlates with heteroplasmy and organ involvement). [21]

---

3. Kearns-Sayre Syndrome (KSS)

Genetics

• Mutation: Large-scale single deletion of mtDNA (typically 1-10 kb deletion).
• Usually sporadic (de novo mutation in oocyte or early embryo).
• NOT maternally inherited in typical cases.
• Deletions remove multiple tRNA genes and protein-coding genes. [10]

Diagnostic Criteria (Classic Triad)

Requires ALL Three:

1. Onset before age 20 years.
2. Progressive external ophthalmoplegia (PEO): Bilateral ptosis and restricted eye movements in all directions (frozen eyes).
3. Pigmentary retinopathy: "Salt-and-pepper" retinopathy on fundoscopy.

Plus at least ONE of:

• Cardiac conduction block (AV block, bundle branch block).
• CSF protein > 1 g/L.
• Cerebellar ataxia. [10]

Clinical Features

Ocular:

• Ptosis: Bilateral, symmetric, slowly progressive. Often severe (head-back posture to see).
• Ophthalmoplegia: Painless, symmetric restriction of eye movements. Patients often unaware (slow progression).
• Pigmentary retinopathy: Granular pigment deposits in retinal periphery.

Cardiac (CRITICAL):

• Progressive cardiac conduction defects: First-degree AV block → second-degree → complete heart block.
• Risk of sudden cardiac death.
• Pacemaker insertion required (often prophylactically).
• Dilated or hypertrophic cardiomyopathy.

Neurological:

• Cerebellar ataxia (gait and limb).
• Cognitive impairment (mild to moderate).
• Proximal myopathy.
• Sensorineural deafness.

Endocrine:

• Short stature.
• Hypoparathyroidism (hypocalcemia).
• Diabetes mellitus.
• Growth hormone deficiency.

Other:

• Elevated CSF protein (often > 1 g/L, mechanism unclear).
• Dysphagia (esophageal dysmotility).
• Renal tubular dysfunction (Fanconi syndrome). [10,22]

Investigations

• ECG: Prolonged PR interval, bundle branch block, AV block (perform regularly—every 6-12 months).
• Echocardiography: Cardiomyopathy, ventricular function.
• MRI Brain: White matter changes, cerebellar atrophy, basal ganglia involvement.
• Muscle Biopsy: Ragged red fibers, COX-negative fibers, abundant mtDNA deletions on molecular analysis.
• CSF: Elevated protein (often dramatically).

Management

• Cardiac: Pacemaker implantation (consider prophylactically even with first-degree block). Regular cardiac monitoring (ECG every 6-12 months, annual echo).
• Ocular: Ptosis crutches (spectacle attachment), ptosis surgery, lubrication for exposure keratopathy.
• Endocrine: Hormone replacement as needed.
• Supportive: CoQ10, physiotherapy.

Prognosis

• Life-threatening cardiac complications (sudden death without pacemaker).
• Progressive disability from ophthalmoplegia, ataxia, myopathy.
• Life expectancy variable (improved significantly with cardiac pacing). [10,22]

---

4. Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)

Genetics

• Highly heterogeneous: > 75 different genetic causes.
• mtDNA mutations: m.8993T>G or m.8993T>C in MT-ATP6 (ATP synthase subunit 6)—causes NARP (Neuropathy, Ataxia, Retinitis Pigmentosa) when heteroplasmy lower, Leigh syndrome when higher.
• nDNA mutations: SURF1 (Complex IV deficiency, most common), NDUFS1-8 (Complex I), SDHA (Complex II), others.
• Inheritance: Maternal (mtDNA) or autosomal recessive (nDNA). [23]

Clinical Features

Onset: Typically infancy to early childhood (peak 3-12 months). Late-onset forms recognized.

Neurological:

• Developmental regression: Loss of motor milestones, cognitive decline.
• Hypotonia: "Floppy baby."
• Dystonia, spasticity: Pyramidal and extrapyramidal signs.
• Ataxia: Cerebellar dysfunction.
• Seizures: Often refractory.
• Brainstem dysfunction: Respiratory irregularities, central apnea, dysphagia, oculomotor abnormalities (nystagmus, ophthalmoplegia).

Systemic:

• Lactic acidosis (persistent elevation).
• Failure to thrive.
• Cardiomyopathy (hypertrophic).
• Hepatopathy.
• Renal tubular acidosis. [23]

Investigations

• Lactate: Markedly elevated (blood and CSF).
• MRI Brain (DIAGNOSTIC):
  • "Bilateral symmetric T2 hyperintensities in:"
    • Basal ganglia (putamen, caudate, globus pallidus).
    • Brainstem (midbrain, pons, medulla).
    • Thalami.
  • Sparing of basal ganglia periphery ("bright swollen basal ganglia" sign).
• MR Spectroscopy: Lactate peak in affected regions.
• Muscle Biopsy: Variable findings—ragged red fibers, COX deficiency (if Complex IV defect), respiratory chain enzyme analysis.
• Genetic Testing: Whole exome sequencing or targeted mitochondrial gene panels.

Management

• Largely Supportive:
  • Nutritional support (gastrostomy often needed).
  • Seizure management.
  • Physiotherapy, occupational therapy.
  • Respiratory support (non-invasive ventilation, tracheostomy).
  • Treat metabolic acidosis (sodium bicarbonate or citrate).
• Experimental:
  • Thiamine (vitamin B1)—may help in some SURF1-related cases.
  • CoQ10, riboflavin.
• Palliative Care: Early involvement for severe cases.

Prognosis

• Generally Poor: Most children die within 2-3 years of symptom onset.
• Respiratory failure is common terminal event.
• Some milder/late-onset cases have prolonged survival.
• No curative treatment currently available. [23]

---

5. Leber Hereditary Optic Neuropathy (LHON)

Genetics

• Three Primary Mutations (account for > 90% of cases):
  • "m.11778G>A (ND4 gene, Complex I): Most common (~50%), worst prognosis for recovery."
  • "m.14484T>C (ND6 gene, Complex I): ~15%, best prognosis for recovery (up to 70% partial recovery)."
  • "m.3460G>A (ND1 gene, Complex I): ~15%, intermediate prognosis."
• Usually homoplasmic (100% mutant).
• Maternal inheritance, but incomplete penetrance. [12,24]

Clinical Features

Ophthalmic (Hallmark):

• Subacute painless visual loss: Central vision loss over days to weeks.
• Sequential involvement: One eye affected, then second eye (weeks to months later). Simultaneous onset in ~25%.
• Age of Onset: Typically young adults (15-35 years, peak 20s), males predominantly affected.
• Central scotoma: Dense cecocentral scotoma on visual field testing.
• Color vision deficits: Red-green dyschromatopsia.
• Visual acuity: Deteriorates to 20/200 or worse (count fingers/hand movements in severe cases).

Fundoscopic Findings:

• Acute Phase: Hyperemia and mild swelling of optic disc ("pseudopapilledema"), peripapillary telangiectatic microangiopathy, retinal nerve fiber layer edema.
• Chronic Phase: Optic atrophy (pale disc), loss of peripapillary retinal nerve fiber layer.

Systemic Features (variable, often absent):

• Cardiac conduction abnormalities (pre-excitation syndromes).
• Postural tremor.
• Peripheral neuropathy.
• Dystonia (rare). [12,24]

Penetrance

• Approximately 50% of males with mutation develop vision loss.
• Approximately 10% of females with mutation develop vision loss.
• Protective effect in females likely hormonal (estrogen protective).

Triggers

• Smoking and alcohol: Strong risk factors for conversion in carriers.
• Toxins, nutritional deficiencies.
• Environmental stressors. [24]

Investigations

• Genetic Testing: Blood sample for m.11778G>A, m.14484T>C, m.3460G>A (first-tier testing).
• OCT (Optical Coherence Tomography): Retinal nerve fiber layer thinning (particularly temporal and inferior).
• Visual Fields: Cecocentral scotoma.
• Color Vision: Ishihara plates show red-green deficiency.
• VEP (Visual Evoked Potentials): Reduced amplitude.
• MRI Orbit/Brain: Typically normal (excludes compressive lesions, demyelination).

Management

• Idebenone: Quinone analogue and antioxidant. Evidence suggests benefit in preserving or recovering vision, particularly if started early and in m.14484T>C mutation carriers. Dose: 900 mg daily. [6,25]
• Avoid Triggers: Smoking cessation, minimize alcohol consumption.
• Supportive: Low vision aids, visual rehabilitation, genetic counseling.
• Investigational: Gene therapy trials ongoing (AAV-mediated ND4 gene replacement showing promise).

Prognosis

• m.11778G>A: Poor—spontaneous recovery rare (less than 10%).
• m.14484T>C: Favorable—up to 70% experience some visual recovery within 1 year.
• m.3460G>A: Intermediate—approximately 20-40% partial recovery.
• Recovery typically incomplete (residual central scotoma common).
• Vision loss is typically permanent and bilateral. [12,24,25]

---

5. Clinical Presentation by System

Mitochondrial diseases are quintessentially multisystem disorders. Clinical suspicion arises when multiple apparently unrelated organ systems are affected, particularly in combination with maternal family history.

Neurological Manifestations

Central Nervous System:

• Stroke-like episodes: MELAS (do NOT follow vascular territories).
• Seizures: Focal, generalized, myoclonic (particularly MERRF), refractory epilepsy.
• Developmental delay/regression: Leigh syndrome, severe infantile presentations.
• Ataxia: Cerebellar degeneration (MERRF, NARP, some Leigh cases).
• Cognitive decline/dementia: Progressive, may mimic neurodegenerative diseases.
• Migraine: Severe headaches, often with aura (MELAS).
• Movement disorders: Dystonia, chorea, parkinsonism.
• Encephalopathy: Acute or chronic.

Peripheral Nervous System:

• Peripheral neuropathy: Sensory, motor, or mixed (axonal or demyelinating).
• Autonomic neuropathy: Orthostatic hypotension, gastroparesis, bowel dysmotility.

Neuromuscular Manifestations

Myopathy:

• Exercise intolerance: Hallmark symptom—muscle fatigue, weakness, pain with exertion.
• Proximal muscle weakness: Difficulty rising from chair, climbing stairs.
• Ptosis: Bilateral, symmetric, slowly progressive (may be isolated or part of CPEO).
• Progressive external ophthalmoplegia (PEO): Restricted eye movements in all directions, often without diplopia (slow progression allows adaptation).
• Rhabdomyolysis: Rare, can be precipitated by infection, anesthesia, exertion.

Cardiac Manifestations

Cardiomyopathy:

• Hypertrophic cardiomyopathy: Left ventricular hypertrophy (often concentric).
• Dilated cardiomyopathy: Reduced ejection fraction, heart failure.

Conduction Defects (particularly KSS):

• First-degree AV block (prolonged PR interval).
• Second-degree AV block (Mobitz I or II).
• Complete heart block: Risk of sudden cardiac death.
• Bundle branch blocks (LBBB, RBBB).
• Pre-excitation syndromes: Wolff-Parkinson-White (MELAS, LHON).

Ophthalmologic Manifestations

Neuro-ophthalmology:

• Optic neuropathy: LHON (acute bilateral sequential vision loss), dominant optic atrophy (OPA1 mutations—gradual bilateral vision loss).
• Ptosis: Bilateral, symmetric (CPEO, KSS).
• Ophthalmoplegia: Restricted eye movements (PEO, KSS).

Retina:

• Pigmentary retinopathy: "Salt-and-pepper" changes (KSS, NARP).
• Retinitis pigmentosa: Night blindness, peripheral visual field loss (NARP).
• Macular pattern dystrophy: m.3243A>G occasionally.

Auditory Manifestations

Sensorineural Deafness:

• Bilateral, progressive hearing loss (high frequencies first).
• Common in MELAS (especially m.3243A>G), MERRF.
• Aminoglycoside-induced deafness: m.1555A>G mutation causes hypersensitivity to aminoglycosides (gentamicin)—even single dose can cause permanent deafness. [26]

Endocrine and Metabolic Manifestations

Diabetes Mellitus:

• MIDD (Maternally Inherited Diabetes and Deafness): m.3243A>G mutation.
• Typical presentation: Lean individual, diabetes onset in third to fourth decade, sensorineural deafness, maternal diabetes.
• Insulin deficiency (β-cell failure), NOT insulin resistance.
• Often requires insulin therapy.

Growth and Development:

• Short stature: Growth hormone deficiency, chronic illness.
• Delayed puberty: Hypogonadotropic hypogonadism.

Parathyroid:

• Hypoparathyroidism: Hypocalcemia, particularly in KSS (treat with calcium and vitamin D).

Adrenal:

• Adrenal insufficiency (rare).

Gastrointestinal Manifestations

Motility Disorders:

• Gastroparesis: Delayed gastric emptying, nausea, vomiting, early satiety.
• Chronic intestinal pseudo-obstruction: Severe dysmotility mimicking bowel obstruction.
• Constipation: Colonic dysmotility.

Hepatic:

• Hepatopathy (elevated transaminases).
• Acute liver failure (particularly with valproate exposure).

Pancreas:

• Exocrine pancreatic insufficiency (rare).

Renal Manifestations

Tubular Dysfunction:

• Fanconi syndrome: Proximal tubular dysfunction with phosphate, glucose, amino acid wasting. Causes rickets/osteomalacia.
• Renal tubular acidosis.
• Focal segmental glomerulosclerosis (FSGS).
• Progressive renal impairment.

Hematologic Manifestations

Pearson Syndrome:

• mtDNA deletion syndrome.
• Sideroblastic anemia: Macrocytic anemia, ringed sideroblasts on bone marrow.
• Exocrine pancreatic dysfunction: Malabsorption, failure to thrive.
• Often fatal in infancy; survivors may evolve to KSS phenotype. [27]

Multisystem Red Flags ("Think Mito")

The following combinations should prompt consideration of mitochondrial disease:

• Diabetes + Deafness (especially lean, young onset, maternal history).
• Ptosis + Ophthalmoplegia + Heart Block (KSS).
• Stroke-like episode + Seizures + Short Stature (MELAS).
• Myoclonus + Ataxia + Epilepsy (MERRF).
• Developmental Regression + Lactic Acidosis + Basal Ganglia Lesions (Leigh).
• Bilateral Sequential Vision Loss in Young Adult Male (LHON).
• Unexplained multisystem disease + elevated lactate + maternal family history.

---

6. Investigations

Initial Screening

Serum Lactate:

• Resting lactate: Often elevated (> 2.5 mmol/L; normal less than 2.0 mmol/L).
• Post-exercise lactate: Exaggerated rise (forearm ischemic exercise test).
• Lactate/pyruvate ratio: Elevated (> 20; normal less than 10) suggests OXPHOS defect.
• Limitations: Can be normal in mitochondrial disease (particularly in non-acute state, blood vs. tissue levels). Requires proper collection (arterial or free-flowing venous, on ice, immediate processing).

CSF Lactate:

• More sensitive for CNS involvement (particularly MELAS, Leigh).
• Elevated: > 2.8 mmol/L (normal less than 2.1 mmol/L).
• CSF protein often elevated (particularly KSS—may exceed 1 g/L). [1,15]

Creatine Kinase (CK):

• Usually normal or mildly elevated (unlike muscular dystrophies).
• Marked elevation suggests rhabdomyolysis.

Glucose:

• Fasting glucose, HbA1c (screen for diabetes).

Liver Function Tests:

• Transaminases may be elevated.

Renal Function:

• Creatinine, urea, bicarbonate.
• Urinalysis: glycosuria (Fanconi syndrome), proteinuria.

Neuroimaging

MRI Brain:

MELAS:

• T2/FLAIR hyperintensity in cortical gray matter (often occipital, parietal, temporal).
• Lesions do NOT respect vascular territories.
• DWI: Restricted diffusion in acute stroke-like episodes.
• May see cortical laminar necrosis.
• Basal ganglia calcification (particularly globus pallidus).

Leigh Syndrome:

• Bilateral symmetric T2 hyperintensities in:
  • Basal ganglia (putamen, caudate, globus pallidus).
  • Brainstem (periaqueductal gray, substantia nigra, inferior olivary nuclei, medial lemniscus).
  • Thalami.
• Central necrosis with peripheral sparing ("bright swollen basal ganglia").

MERRF:

• Cerebellar atrophy.
• Basal ganglia calcification.
• White matter changes.

Kearns-Sayre:

• White matter abnormalities.
• Cerebellar atrophy.
• Basal ganglia calcification. [1,28]

MR Spectroscopy:

• Lactate peak (doublet at 1.3 ppm) in affected brain regions.
• Reduced N-acetylaspartate (NAA)—neuronal loss/dysfunction.

Cardiac Investigations

ECG:

• Essential in all patients, particularly KSS/CPEO.
• Repeat every 6-12 months (conduction defects progress).
• Findings: PR prolongation, bundle branch blocks, AV blocks, pre-excitation (short PR, delta wave).

Echocardiography:

• Assess for cardiomyopathy (hypertrophic vs. dilated).
• Ventricular function (ejection fraction).
• Annual or biannual surveillance. [10]

Holter Monitor:

• Detect intermittent arrhythmias, conduction abnormalities.

Ophthalmologic Investigations

Fundoscopy:

• Pigmentary retinopathy (KSS, NARP).
• Optic atrophy (LHON, dominant optic atrophy).
• Optic disc swelling (acute LHON).

Optical Coherence Tomography (OCT):

• Retinal nerve fiber layer (RNFL) thinning (LHON, optic atrophy).

Visual Fields:

• Cecocentral scotoma (LHON).

Electroretinography (ERG):

• Retinal dysfunction (NARP, pigmentary retinopathy).

Audiology

Pure Tone Audiometry:

• Sensorineural hearing loss (high-frequency first).
• Bilateral, progressive.

Muscle Biopsy

Indications:

• Suspected mitochondrial myopathy.
• Confirm OXPHOS defect.
• Measure heteroplasmy levels (muscle often higher than blood).

Sampling:

• Open biopsy preferred (adequate tissue for multiple analyses).
• Site: Deltoid or vastus lateralis (clinically affected muscle, but NOT end-stage fibrotic).
• Avoid local anesthetic with adrenaline (causes artifacts).

Histology and Histochemistry:

Gomori Trichrome Stain:

• Ragged Red Fibers (RRF): Subsarcolemmal accumulation of abnormal mitochondria (red-staining peripheral zones).
• Highly suggestive of mitochondrial disease (though not entirely specific).

Cytochrome c Oxidase (COX) Stain:

• COX-negative fibers: Brown staining absent (complex IV deficiency).
• "Mosaic pattern" or "checkerboard" pattern: Mixture of COX-positive (brown) and COX-negative (pale) fibers.
• COX-negative/SDH-positive fibers highly specific for mitochondrial disease.

Succinate Dehydrogenase (SDH) Stain:

• Overactivity in mitochondria-rich fibers (dark blue).
• "Ragged blue fibers."

Electron Microscopy:

• Mitochondrial accumulation (subsarcolemmal, intermyofibrillar).
• Abnormal mitochondrial morphology: "Parking lot" crystalline inclusions, concentric cristae. [16,28]

Biochemical Analysis (Respiratory Chain Enzyme Activities):

• Measure activities of Complexes I-IV in muscle homogenate.
• Identifies specific complex deficiency.
• Requires fresh/frozen tissue. [1]

Genetic Testing

First-Tier Testing (Based on Phenotype):

MELAS suspected:

• Blood or urine epithelial cells for m.3243A>G.
• If negative and suspicion high: muscle biopsy for mtDNA sequencing (heteroplasmy may be muscle-specific).

MERRF suspected:

• Blood for m.8344A>G.

LHON suspected:

• Blood for m.11778G>A, m.14484T>C, m.3460G>A (captures > 90%).

Leigh syndrome suspected:

• Whole exome sequencing (WES) or mitochondrial gene panel (> 75 genes).
• Consider m.8993T>G/T>C in MT-ATP6.

Kearns-Sayre suspected:

• Muscle biopsy for large-scale mtDNA deletions (often absent in blood).

Second-Tier Testing:

• Whole mtDNA sequencing: If targeted testing negative.
• Whole exome sequencing (WES) or whole genome sequencing (WGS): Identify nuclear gene defects.
• mtDNA deletion/depletion analysis: Quantitative assays. [29]

Interpretive Challenges:

• Heteroplasmy levels vary between tissues (blood may not reflect muscle/brain).
• Variants of uncertain significance (VUS): mtDNA has high sequence variation; pathogenicity assessment challenging.
• ACMG/AMP guidelines for mtDNA variant interpretation published to standardize classification. [29]

---

7. Management

General Principles

Mitochondrial disease management remains largely supportive, focused on symptomatic treatment, preventing complications, and optimizing quality of life. No curative therapies currently exist for most mitochondrial diseases, though disease-modifying treatments are emerging for specific conditions. [5,30]

Multidisciplinary Care:

• Neurology, cardiology, endocrinology, ophthalmology, audiology, genetics.
• Physiotherapy, occupational therapy, speech therapy, dietetics.
• Palliative care (for severe progressive cases).

Acute Management

MELAS Stroke-Like Episodes

L-Arginine Therapy:

• Mechanism: Nitric oxide (NO) precursor; mitochondrial angiopathy causes NO deficiency and impaired cerebrovascular reactivity. Arginine supplementation improves cerebral perfusion. [20]
• Acute Protocol:
  • "IV L-Arginine: 500 mg/kg bolus over 30-60 minutes (maximum 30 g)."
  • "Followed by continuous infusion: 100-200 mg/kg/day for 3-5 days."
  • Monitor blood pressure (hypotension possible).
• Evidence: Case series and observational studies suggest reduced severity and frequency of strokes. [20,31]

Seizure Management:

• Treat aggressively (seizures worsen metabolic stress).
• Avoid valproate (mitochondrial toxicity—see below).
• Use levetiracetam, lamotrigine, benzodiazepines (lorazepam, midazolam).

Supportive:

• IV fluids (hydration helps lactate clearance).
• Treat precipitants (infections, dehydration).
• Avoid hypoglycemia, hypoxia.
• Neuroimaging to exclude alternative diagnoses (hemorrhage, infection).

Lactic Acidosis

Mild Chronic Elevation (2.5-5 mmol/L):

• Usually asymptomatic, requires no specific treatment.

Severe Acute Acidosis (> 5-10 mmol/L, pH less than 7.2):

• Treat underlying precipitant (infection, metabolic stressor).
• Sodium bicarbonate or sodium citrate (oral or IV) to correct acidosis.
• Hydration (promote lactate clearance).
• Avoid worsening ATP deficit (infection control, supportive care).
• Hemodialysis if refractory (rare).

Metabolic Decompensation

Precipitants: Infection, fasting, surgery, anesthesia.

Management:

• Treat infection aggressively (antibiotics, antipyretics).
• Avoid prolonged fasting (IV dextrose if NPO).
• Maintain normoglycemia.
• Supportive care (fluids, electrolyte management).

Chronic Management

Nutritional and Exercise Interventions

Diet:

• Avoid prolonged fasting: Triggers catabolic state, worsens energy deficit.
• Frequent meals, complex carbohydrates.
• Ketogenic diet generally NOT recommended (requires intact mitochondria for ketone oxidation).

Exercise:

• Aerobic exercise (moderate intensity) may promote mitochondrial biogenesis and improve function.
• Avoid excessive exertion (may precipitate rhabdomyolysis).
• Individualized exercise programs with physiotherapy. [30]

"Mitochondrial Cocktail" (Vitamin and Cofactor Supplementation)

Rationale: Provide substrates and cofactors to bypass or compensate for OXPHOS defects.

Evidence: Largely anecdotal or small studies; no large randomized controlled trials demonstrate clear benefit. Nonetheless, widely used given low risk and potential benefit. [30,32]

Components:

Coenzyme Q10 (Ubiquinone/Ubiquinol):

• Electron carrier between Complexes I/II and Complex III.
• Antioxidant.
• Dose: 300-600 mg/day (ubiquinol may have better bioavailability).
• Best evidence in primary CoQ10 deficiency (CoQ10 biosynthesis defects—these respond dramatically). [32]

Riboflavin (Vitamin B2):

• Precursor of FAD, cofactor for Complexes I and II.
• Dose: 100-400 mg/day.

Thiamine (Vitamin B1):

• Cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (Krebs cycle enzymes).
• Dose: 100-300 mg/day.

L-Carnitine:

• Facilitates fatty acid transport into mitochondria (β-oxidation).
• Dose: 50-100 mg/kg/day (divided doses).
• Monitor for "fishy" body odor (trimethylamine accumulation).

Creatine Monohydrate:

• Energy buffer (phosphocreatine shuttle).
• Dose: 5-10 g/day.

Alpha-Lipoic Acid:

• Antioxidant, cofactor for pyruvate dehydrogenase.
• Dose: 300-600 mg/day.

Vitamin C and Vitamin E:

• Antioxidants (reduce ROS damage).
• Doses: Vitamin C 500-1000 mg/day, Vitamin E 400 IU/day.

Folinic Acid (Leucovorin):

• For cerebral folate deficiency (KSS cases).
• Dose: 15-30 mg/day. [30,32]

Disease-Specific Pharmacological Therapies

Idebenone (LHON):

• Synthetic quinone analogue, antioxidant, alternative electron carrier.
• Indication: LHON (all three primary mutations).
• Dose: 900 mg/day (divided doses).
• Evidence: RHODOS trial (randomized controlled trial) showed benefit in visual recovery, particularly m.14484T>C carriers and recent onset (less than 1 year). [6,25]
• Approved in Europe for LHON treatment.

L-Arginine and L-Citrulline (MELAS):

• Prophylaxis of stroke-like episodes.
• Dose: L-Arginine 150-300 mg/kg/day (divided) or L-Citrulline 150-200 mg/kg/day (better GI tolerance).
• Some evidence for reduced stroke frequency. [20,31]

EPI-743 (Investigational):

• Synthetic quinone, antioxidant.
• Studied in Leigh syndrome, other mitochondrial diseases.
• Results mixed; not yet approved.

Organ-Specific Management

Cardiac:

• Pacemaker implantation: For KSS, CPEO with any conduction abnormality (even first-degree AV block—consider prophylactically). [10]
• Heart failure management: Standard therapies (ACE inhibitors, beta-blockers, diuretics) for cardiomyopathy.
• ICD (Implantable Cardioverter-Defibrillator): Consider if ventricular arrhythmias or severe cardiomyopathy.
• Regular monitoring: ECG every 6-12 months, annual echocardiography.

Ophthalmologic:

• Ptosis correction: Ptosis crutches (spectacle attachment), frontalis sling surgery, levator resection (caution—may worsen ophthalmoplegia or cause exposure keratopathy).
• Lubrication: Artificial tears, nighttime ointment (exposure keratopathy from lagophthalmos).
• Low vision aids: Magnifiers, high-contrast materials (LHON, optic atrophy).

Endocrine:

• Diabetes management: Insulin therapy (often required—β-cell dysfunction). Metformin contraindicated (inhibits Complex I, risk of lactic acidosis). [33]
• Hormone replacement: Growth hormone, sex hormones, thyroid hormone, calcium/vitamin D (hypoparathyroidism) as indicated.

Epilepsy:

• First-line: Levetiracetam, lamotrigine, lacosamide.
• For myoclonus: Clonazepam, piracetam, zonisamide.
• AVOID VALPROATE (see below).

Hearing Loss:

• Hearing aids, cochlear implantation (selected cases).
• Avoid aminoglycosides (gentamicin, tobramycin, amikacin) in patients with m.1555A>G mutation (even single dose can cause irreversible deafness). [26]

Gastrointestinal:

• Gastroparesis: Metoclopramide (caution—extrapyramidal side effects), domperidone, erythromycin (prokinetic).
• Pseudo-obstruction: Nutritional support, gastrostomy/jejunostomy feeding.

Anesthesia:

• Mitochondrial disease patients at risk for complications (metabolic stress).
• Precautions: Avoid prolonged fasting (IV dextrose), maintain normothermia, optimize metabolic state, monitor lactate.
• Avoid propofol infusion syndrome (prolonged high-dose propofol—causes mitochondrial dysfunction and lactic acidosis). [34]

Contraindicated and Caution Medications

AVOID:

Valproate (Sodium Valproate, Valproic Acid, Divalproex):

• CONTRAINDICATED in mitochondrial disease (particularly POLG mutations).
• Mechanisms: Inhibits β-oxidation, depletes carnitine and CoA, direct mitochondrial toxicity.
• Can precipitate acute hepatic failure, encephalopathy, death.
• Black box warning in many jurisdictions for POLG-related disorders. [11,35]

Metformin:

• Inhibits Complex I.
• Risk of lactic acidosis.
• Contraindicated in mitochondrial diabetes (use insulin instead). [33]

Aminoglycosides (Gentamicin, Tobramycin, Amikacin):

• Mitochondrial toxicity.
• Absolutely contraindicated in m.1555A>G carriers (even single dose causes permanent deafness).
• Caution in all mitochondrial disease patients. [26]

Linezolid:

• Inhibits mitochondrial protein synthesis (binds mitochondrial ribosome).
• Prolonged use can cause optic neuropathy, lactic acidosis, peripheral neuropathy.
• Use with caution, shortest duration possible. [36]

Propofol (Prolonged Infusion):

• Propofol infusion syndrome: Mitochondrial dysfunction, rhabdomyolysis, cardiac failure, lactic acidosis.
• Avoid prolonged high-dose propofol infusions in ICU (short-term anesthetic use generally safe). [34]

Caution:

• Statins: Myopathy risk (already have mitochondrial myopathy—may worsen).
• Alcohol: Mitochondrial toxin, LHON trigger.
• Tobacco: LHON trigger.

Monitoring and Surveillance

Annual Assessments (minimum):

• Neurology: Clinical assessment, monitor disease progression.
• Cardiology: ECG (6-12 monthly if cardiac involvement), echocardiography.
• Ophthalmology: Fundoscopy, visual acuity, OCT (if optic neuropathy/retinopathy).
• Audiology: Pure tone audiometry.
• Endocrinology: Glucose, HbA1c, thyroid function, growth parameters (children).
• Dietetics: Nutritional assessment.

Exercise Tolerance Testing:

• 6-minute walk test, cardiopulmonary exercise testing (CPET)—monitor disease progression, guide rehabilitation.

Quality of Life:

• Psychological support, patient support groups (e.g., Mito Foundation, United Mitochondrial Disease Foundation).

---

8. Prevention and Genetic Counseling

Reproductive Counseling

Maternal mtDNA Mutations

Inheritance:

• Affected mothers transmit mutation to all offspring (100% transmission).
• Heteroplasmy unpredictable: Mitochondrial bottleneck causes wide variance in offspring heteroplasmy levels (mother with 30% mutant may have child with 5% or 90% mutant). [9,18]

Recurrence Risk:

• Cannot be precisely predicted.
• Correlation between maternal and offspring heteroplasmy weak.
• Prenatal/preimplantation testing limited utility (heteroplasmy may shift during development).

Reproductive Options:

Oocyte Donation:

• Donor egg with partner's sperm.
• Avoids mtDNA transmission (donor's mtDNA transmitted instead).
• Standard option currently available.

Mitochondrial Replacement Therapy (MRT) (see below):

• Prevents mtDNA transmission while preserving nuclear genetic contribution.
• Legal in UK, under consideration elsewhere. [37]

Preimplantation Genetic Diagnosis (PGD):

• Embryo biopsy during IVF, select embryos with lowest heteroplasmy.
• Limited efficacy: Heteroplasmy can change during development (bottleneck effect).
• Some centers offer for specific mutations.

Nuclear DNA Mutations

Autosomal Recessive:

• 25% recurrence risk for subsequent children.
• Carrier testing for partners recommended.
• Prenatal diagnosis (amniocentesis, CVS) available if mutation known.
• Preimplantation genetic diagnosis (PGD) available.

Autosomal Dominant:

• 50% transmission risk.
• Variable penetrance and expressivity common.
• Prenatal diagnosis and PGD available.

X-Linked:

• Carrier females: 50% risk to male offspring (affected), 50% risk to female offspring (carriers).
• Affected males (if viable): All daughters carriers, all sons unaffected.
• Prenatal diagnosis and PGD available. [1]

Mitochondrial Replacement Therapy (MRT)

Concept: "Three-Parent IVF"—technique to prevent transmission of pathogenic mtDNA mutations from mother to offspring.

Techniques:

Maternal Spindle Transfer (MST):

1. Remove nuclear spindle (containing maternal chromosomes) from mother's unfertilized egg (MII oocyte).
2. Enucleate donor egg (remove donor nuclear spindle).
3. Transfer mother's nuclear spindle into enucleated donor egg.
4. Fertilize reconstructed egg with partner's sperm.
5. Resulting embryo has mother's nuclear DNA + donor's mtDNA + father's nuclear DNA. [37,38]

Pronuclear Transfer (PNT):

1. Fertilize mother's egg and donor egg with partner's sperm (creates zygotes).
2. Remove pronuclei (containing maternal and paternal chromosomes) from mother's zygote.
3. Remove pronuclei from donor zygote (discard).
4. Transfer parental pronuclei into enucleated donor zygote.
5. Resulting embryo has parental nuclear DNA + donor mtDNA. [37,38]

Outcome:

• Offspring have less than 1% maternal mtDNA (rest is donor mtDNA).
• Nuclear genome entirely from parents (physical traits, genetic identity).
• Avoids transmission of pathogenic mtDNA mutations.

Regulatory Status:

• UK: Legal since 2015 (HFEA licensed). First births reported 2016-2017.
• Australia: Legal since 2022.
• USA: Not approved by FDA.
• Many countries: Under consideration or prohibited. [37,38]

Ethical Considerations:

• Germline modification: Changes transmitted to future generations.
• "Designer babies" concerns: Mischaracterization (does not alter nuclear genes—physical/mental traits unchanged).
• Safety: Long-term outcomes unknown. Potential nucleo-mitochondrial incompatibility (theoretical).
• Identity: "Three genetic parents" (though mtDNA contribution is less than 0.1% of total DNA).
• Regulation: Requires robust oversight. [37,38]

Efficacy:

• Prevents severe mitochondrial disease in high-risk families.
• Small number of births reported; outcomes favorable to date.
• Carryover: Low-level maternal mtDNA carryover (less than 2%) occasionally detected; clinical significance unclear. [37,38]

---

9. Prognosis

Prognosis in mitochondrial disease is highly variable, determined by:

• Genetic defect (mutation type).
• Heteroplasmy level (percentage mutant mtDNA).
• Organ involvement (cardiac, CNS involvement worsens prognosis).
• Age of onset (earlier onset generally more severe).

Syndrome-Specific Prognosis

MELAS:

• Progressive neurological decline with recurrent stroke-like episodes.
• Cumulative brain injury causes dementia, disability.
• Life expectancy reduced (median survival approximately 30-40 years in severe cases, though highly variable).
• Sudden death risk (cardiac arrhythmias, status epilepticus).

MERRF:

• Progressive ataxia, myoclonus, epilepsy, dementia.
• Wheelchair dependency common by third to fourth decade.
• Variable life expectancy (some survive to fifth or sixth decade).

Kearns-Sayre Syndrome:

• Progressive ophthalmoplegia, ataxia, muscle weakness cause significant disability.
• Cardiac conduction defects life-threatening (sudden cardiac death) WITHOUT pacemaker.
• Prognosis improved substantially with pacemaker insertion.
• Survival into fifth or sixth decade possible with appropriate management. [10]

Leigh Syndrome:

• Generally poor prognosis: Majority die within 2-3 years of onset.
• Respiratory failure common terminal event.
• Some milder presentations (later onset, specific genotypes) have prolonged survival.
• Severely affects quality of life; palliative care often appropriate. [23]

LHON:

• Vision loss typically permanent and bilateral.
• Recovery depends on mutation: m.14484T>C best (up to 70% partial recovery), m.11778G>A worst (less than 10% recovery).
• Does not affect life expectancy.
• Disability from blindness significant. [24,25]

Chronic Progressive External Ophthalmoplegia (CPEO):

• Slowly progressive ptosis and ophthalmoplegia.
• Often milder systemic involvement than KSS.
• Near-normal life expectancy if no cardiac involvement.
• Requires cardiac surveillance.

Predictors of Poor Prognosis

• Early age of onset (infancy, early childhood).
• Severe multisystem involvement (particularly cardiac, CNS).
• High heteroplasmy levels (> 80-90%).
• Specific mutations (e.g., m.8993T>G with > 90% heteroplasmy causes severe Leigh syndrome).
• Lactic acidosis (persistent severe elevation).
• Cardiac conduction defects without pacemaker.

Quality of Life

• Mitochondrial diseases cause significant morbidity: chronic pain, fatigue, disability, sensory deficits.
• Multidisciplinary supportive care improves quality of life.
• Patient advocacy and support groups valuable (Mito Foundation, UMDF, Lily Foundation).

---

10. Future Directions and Emerging Therapies

Gene Therapy

Allotopic Expression:

• Transfer mtDNA-encoded genes into nuclear genome, with mitochondrial targeting sequences.
• Protein expressed in nucleus, imported into mitochondria.
• Challenges: Genetic code differences (mtDNA uses alternative genetic code), protein import efficiency.

AAV-Mediated Gene Therapy (LHON):

• Adeno-associated virus (AAV) delivers wild-type ND4 gene (m.11778G>A mutation) directly to retinal ganglion cells.
• Clinical trials ongoing: GS010 (LUMEVOQ) showing promise (vision stabilization/improvement in treated eyes). [39]
• Potential approval in Europe.

mtDNA Editing:

• Selective degradation of mutant mtDNA using mitochondrial-targeted restriction endonucleases or base editors.
• Proof-of-concept in animal models.
• Not yet in clinical trials. [40]

Small Molecule Therapies

KH176 (Sonlicromanol):

• Redox-modulating agent (derivative of vitamin E).
• Phase 2 trial in mitochondrial disease (m.3243A>G mutation): Improved patient-reported outcomes, reduced biomarkers. [41]
• Phase 3 trial planned.

Elamipretide (MTP-131, Bendavia):

• Mitochondria-targeting peptide, stabilizes cardiolipin (inner membrane lipid), improves OXPHOS efficiency.
• Studied in mitochondrial myopathy, heart failure, other conditions.
• Mixed results; further trials ongoing. [42]

NAD+ Precursors:

• Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) boost NAD+ levels (coenzyme for redox reactions).
• May enhance mitochondrial function.
• Early clinical trials ongoing. [43]

Mitochondrial Augmentation Therapies

Autologous Mitochondrial Transplantation:

• Harvest healthy mitochondria from patient's own tissue, inject into affected tissue.
• Studied in cardiac ischemia-reperfusion injury.
• Potential for focal mitochondrial disease (e.g., LHON—inject into optic nerve/retina).

Stem Cell Therapy:

• Mesenchymal stem cells (MSCs) may transfer healthy mitochondria to damaged cells.
• Preclinical studies, early clinical trials. [44]

Exercise and Lifestyle Interventions

• Emerging evidence that structured aerobic exercise programs improve mitochondrial biogenesis, oxidative capacity, exercise tolerance.
• "Mitochondrial medicine clinics" developing standardized exercise protocols. [30]

---

11. Case Studies

Case A: The "Migraine" Patient

Presentation:

• 22-year-old woman presents to emergency department with severe occipital headache, nausea, vomiting, and visual field defect (right homonymous hemianopia).
• History: Long-standing migraines (since age 12), sensorineural deafness (diagnosed age 10), short stature (5th percentile).
• Family history: Mother has diabetes (diagnosed age 35) and hearing loss. Maternal aunt died age 28 ("stroke").

Examination:

• Alert, oriented. Right homonymous hemianopia. Fundoscopy normal. No weakness.
• Height 150 cm, weight 45 kg (lean build).

Investigations:

• CT head (non-contrast): No hemorrhage, subtle left occipital hypodensity.
• MRI brain: T2/FLAIR hyperintensity in left occipital cortex extending across vascular territories, with cortical swelling. DWI shows restricted diffusion.
• Serum lactate: 5.2 mmol/L.
• CSF lactate: 3.8 mmol/L. CSF protein 0.6 g/L.
• Genetic testing: m.3243A>G mutation detected in blood (heteroplasmy 35%).

Diagnosis: MELAS (stroke-like episode).

Management:

• IV L-Arginine (500 mg/kg bolus, then infusion).
• Levetiracetam for seizure prophylaxis.
• Hydration.
• Avoided thrombolysis (not ischemic stroke).

Outcome:

• Visual field defect partially improved over 2 weeks (residual right superior quadrantanopsia).
• Started prophylactic oral L-Arginine, CoQ10.
• Counseled regarding stroke risk, family planning (mitochondrial replacement therapy discussed).

Key Learning: Stroke-like episodes in young patient with diabetes, deafness, short stature, maternal family history → think MELAS.

---

Case B: The "Floppy Baby"

Presentation:

• 8-month-old infant referred for developmental delay.
• Parents report: Not sitting unsupported, poor head control, weak cry.
• Born at term, normal delivery. Initially developmentally appropriate; regression noticed at 5 months.

Examination:

• Severe hypotonia ("floppy"). Weak suck, poor feeding.
• Absent developmental milestones (cannot roll, sit, or grasp objects).
• Optic atrophy on fundoscopy.

Investigations:

• Serum lactate: 8.5 mmol/L (markedly elevated).
• MRI brain: Bilateral symmetric T2 hyperintensities in putamen, caudate, and midbrain periaqueductal gray matter. MR spectroscopy: Lactate peak.
• Muscle biopsy: COX-deficient fibers. Respiratory chain enzyme analysis: Complex IV activity severely reduced.
• Genetic testing: SURF1 gene mutations (compound heterozygous, autosomal recessive).

Diagnosis: Leigh Syndrome (Complex IV deficiency).

Management:

• Supportive care: Gastrostomy feeding (failure to thrive, aspiration risk).
• CoQ10, thiamine supplementation (limited efficacy).
• Palliative care team involvement.

Outcome:

• Progressive neurological decline.
• Respiratory failure (central apnea) at 18 months, required tracheostomy and ventilation.
• Died age 22 months.

Family Counseling:

• Autosomal recessive inheritance: 25% recurrence risk.
• Carrier testing offered to parents and extended family.
• Prenatal diagnosis available for future pregnancies.

Key Learning: Developmental regression + lactic acidosis + bilateral basal ganglia lesions → Leigh syndrome. Prognosis generally poor. Palliative care essential.

---

Case C: The "Blind Young Man"

Presentation:

• 24-year-old man presents with 6-week history of painless vision loss, right eye.
• Vision deteriorated from 20/20 to "blurry central vision" over 2 weeks. Now difficulty reading, recognizing faces.
• No eye pain, no headache.
• Three weeks later, left eye vision begins to deteriorate similarly.

Examination:

• Visual acuity: Right eye 20/200, left eye 20/60.
• Ishihara color plates: Severe red-green dyschromatopsia bilaterally.
• Visual fields: Dense cecocentral scotomas bilaterally.
• Fundoscopy: Right eye—optic disc pallor (atrophy). Left eye—optic disc hyperemia, peripapillary telangiectasia.
• Pupils: Sluggish light reaction. No RAPD (bilateral disease).

Investigations:

• MRI brain and orbits: Normal (no optic nerve enhancement, no mass).
• OCT: Severe RNFL thinning (temporal and inferior sectors) bilaterally.
• Genetic testing (blood): m.11778G>A mutation (homoplasmic, 100%).

Diagnosis: Leber Hereditary Optic Neuropathy (LHON).

Management:

• Idebenone 900 mg daily started immediately.
• Smoking cessation counseling (patient was smoker—15 cigarettes/day).
• Alcohol avoidance.
• Low vision rehabilitation (magnifiers, contrast aids).

Family Screening:

• Mother (asymptomatic): m.11778G>A carrier (homoplasmic).
• Sister (asymptomatic): m.11778G>A carrier (homoplasmic).
• Counseled on smoking/alcohol avoidance, watch for visual symptoms.

Outcome:

• Vision stabilized at 20/200 (right), 20/100 (left) after 6 months.
• No recovery (m.11778G>A has poorest prognosis for recovery).
• Registered as legally blind; uses mobility aids.

Key Learning: Bilateral sequential painless vision loss in young man → LHON. Idebenone started early. Avoid smoking/alcohol. Genetic counseling for family (maternal inheritance).

---

12. Examination Focus

High-Yield Exam Topics

Histology

Q: What is the hallmark histological finding on muscle biopsy in mitochondrial disease?
A: Ragged red fibers on Gomori trichrome stain (subsarcolemmal accumulation of abnormal mitochondria). COX-negative fibers (cytochrome c oxidase deficiency) on COX stain are also highly characteristic ("mosaic" or "checkerboard" pattern).

Genetics and Inheritance

Q: A mother with MELAS (m.3243A>G mutation) asks about risk to her children. What is the inheritance pattern?
A: Maternal inheritance—all offspring will inherit the mutation (100% transmission). However, heteroplasmy level in offspring is unpredictable due to the mitochondrial bottleneck (offspring may have higher or lower mutant load than mother). Phenotypic severity depends on heteroplasmy level.

Q: A father with LHON asks about risk to his children. What is the risk?
A: Zero risk—paternal mitochondria are not transmitted to offspring. All mtDNA is maternally inherited.

Q: Why can two siblings with the same mtDNA mutation have dramatically different phenotypes?
A: Heteroplasmy (percentage of mutant vs. wild-type mtDNA) varies between individuals due to mitochondrial bottleneck during oogenesis and mitotic segregation. Threshold effect: Symptoms appear when mutant load exceeds critical level (typically 60-90%), which differs between siblings.

Pharmacology and Contraindications

Q: Which antiepileptic drug is absolutely contraindicated in mitochondrial disease? Why?
A: Sodium valproate (valproic acid). Mechanisms: Inhibits β-oxidation, depletes carnitine, causes direct mitochondrial toxicity. Can precipitate acute hepatic failure, encephalopathy, and death (particularly in POLG mutations). Use levetiracetam, lamotrigine, or benzodiazepines instead.

Q: Which oral hypoglycemic agent is contraindicated in mitochondrial diabetes?
A: Metformin—inhibits Complex I of the electron transport chain and increases risk of lactic acidosis. Use insulin instead.

Q: A patient with mitochondrial disease and the m.1555A>G mutation develops pneumonia. Which antibiotic class should be avoided?
A: Aminoglycosides (gentamicin, tobramycin, amikacin). The m.1555A>G mutation causes hypersensitivity to aminoglycosides—even a single dose can cause permanent sensorineural deafness.

Clinical Syndromes

Q: A 25-year-old woman with diabetes, deafness, and short stature presents with acute aphasia and confusion. MRI shows cortical T2 hyperintensity in the left temporal lobe that does NOT respect vascular territories. Lactate is elevated. What is the diagnosis and acute treatment?
A: MELAS (stroke-like episode). Acute treatment: IV L-Arginine (500 mg/kg bolus, then infusion)—nitric oxide donor improves cerebral perfusion. Avoid thrombolysis (not ischemic stroke). Treat seizures (avoid valproate).

Q: What are the diagnostic criteria for Kearns-Sayre syndrome?
A: Requires ALL three:

1. Onset less than 20 years.
2. Progressive external ophthalmoplegia (PEO).
3. Pigmentary retinopathy.
   PLUS at least one: Cardiac conduction block, CSF protein > 1 g/L, cerebellar ataxia.

Q: Why do Kearns-Sayre patients require pacemakers?
A: Progressive cardiac conduction defects (AV block) develop and can cause sudden cardiac death. Pacemaker insertion (often prophylactic, even with first-degree AV block) is life-saving. Regular ECG monitoring (every 6-12 months) essential.

Q: Which mitochondrial disease predominantly affects young males and causes bilateral sequential vision loss?
A: Leber Hereditary Optic Neuropathy (LHON). Peak onset 20s. Males affected 60-90% of cases (hormonal protection in females). Mutations in Complex I genes (m.11778G>A most common). Fundoscopy shows optic disc hyperemia acutely, optic atrophy chronically.

Q: What is the typical MRI finding in Leigh syndrome?
A: Bilateral symmetric T2 hyperintensities in basal ganglia (putamen, caudate), brainstem (periaqueductal gray, substantia nigra), and thalami. Central necrosis with peripheral sparing. MR spectroscopy shows lactate peak.

Biochemistry

Q: What is the biochemical hallmark of mitochondrial disease?
A: Elevated lactate (blood and CSF) with elevated lactate/pyruvate ratio (> 20, normal less than 10). Reflects shift to anaerobic glycolysis due to OXPHOS defect. CSF lactate more sensitive for CNS involvement.

Q: Why is creatine kinase (CK) usually normal or only mildly elevated in mitochondrial myopathy (unlike muscular dystrophies)?
A: Mitochondrial diseases cause energy deficiency rather than muscle membrane breakdown (sarcolemmal rupture). Dystrophies cause membrane fragility and myofiber necrosis → CK release. In mitochondrial disease, muscle fibers remain intact but energetically impaired.

Pathophysiology

Q: What is the "threshold effect" in mitochondrial disease?
A: Clinical manifestations appear only when the percentage of mutant mtDNA exceeds a critical threshold in affected tissue (typically 60-90%). Below threshold, wild-type mtDNA compensates. This explains variable expressivity and incomplete penetrance.

Q: Explain the "mitochondrial bottleneck" and its clinical significance.
A: During oogenesis, mtDNA copy number transiently decreases to ~200 molecules before amplifying to ~100,000 in mature oocyte. This sampling creates random variance in heteroplasmy between offspring. Result: Mother with 30% mutant can produce offspring with 5-90% mutant (unpredictable). Complicates reproductive counseling.

Treatment

Q: What is the evidence for Coenzyme Q10 (ubiquinone) supplementation in mitochondrial disease?
A: Best evidence in primary CoQ10 deficiency (CoQ10 biosynthesis defects)—these patients respond dramatically. For other mitochondrial diseases, evidence is weak (anecdotal, small studies, no large RCTs). Nonetheless, widely used (low risk, potential benefit). Typical dose 300-600 mg/day.

Q: Which mitochondrial disease has an approved pharmacological treatment with good evidence?
A: LHON—Idebenone (900 mg/day), synthetic quinone and antioxidant. RHODOS trial (RCT) showed benefit in visual recovery, particularly m.14484T>C mutation and recent onset (less than 1 year). Approved in Europe.

---

13. Red Flags and Clinical Pearls Summary

Red Flags (Emergency Presentations)

1. Stroke-like episode in young patient (especially with diabetes, deafness, short stature) → MELAS—IV L-Arginine, avoid thrombolysis.
2. Progressive AV block on ECG (especially with ptosis, ophthalmoplegia) → Kearns-Sayre—urgent pacemaker evaluation.
3. Acute bilateral vision loss in young male → LHON—start idebenone, smoking/alcohol cessation.
4. Developmental regression + lactic acidosis + basal ganglia lesions → Leigh syndrome—palliative care involvement.
5. Severe lactic acidosis (> 10 mmol/L, pH less than 7.2) → Metabolic emergency—treat precipitant (infection), bicarbonate, ICU.
6. Respiratory failure in infant with mitochondrial disease → Leigh syndrome, consider palliative approach.

Clinical Pearls for Exams

• "Diabetes + Deafness" = Think mitochondrial disease (especially lean, maternal history) → m.3243A>G.
• "Stroke that doesn't follow vessels" = MELAS (cortical, often posterior, not respecting vascular territories).
• "Ragged red fibers" = Subsarcolemmal mitochondrial accumulation (Gomori trichrome stain).
• "COX-negative fibers" = Complex IV (cytochrome c oxidase) deficiency—mosaic pattern highly specific.
• "Maternal inheritance" = Affects all offspring, but heteroplasmy unpredictable.
• "Paternal inheritance" = Does NOT occur (except extremely rare cases).
• "Heteroplasmy threshold" = Need ~70-90% mutant for symptoms (tissue-dependent).
• "Valproate = Poison" in mitochondrial disease → Avoid (use levetiracetam, lamotrigine).
• "Metformin contraindicated" in mitochondrial diabetes → Use insulin.
• "Aminoglycosides + m.1555A>G = Deafness" → Avoid gentamicin.
• "Ptosis + Ophthalmoplegia = Check ECG" → Rule out cardiac conduction defects (KSS).
• "Three-parent baby" = Mitochondrial replacement therapy (MRT)—legal in UK, prevents mtDNA disease transmission.

---

14. Patient and Layperson Explanation

What is Mitochondrial Disease?

Mitochondria are tiny "power plants" inside every cell in your body. They convert food (glucose, fats) and oxygen into energy (ATP) that your cells use to function. In mitochondrial disease, these power plants don't work properly, so your cells don't get enough energy.

Organs that need lots of energy—like your brain, muscles, heart, and eyes—are affected most. This is why mitochondrial diseases cause such varied symptoms: seizures, muscle weakness, vision loss, heart problems, diabetes, and more.

Why Do I Have It?

Mitochondria have their own DNA (mtDNA), separate from the DNA in your cell nucleus. Mitochondrial disease is caused by mutations (errors) in either:

• Mitochondrial DNA (mtDNA): Inherited from your mother (only mothers pass mtDNA to children).
• Nuclear DNA (nDNA): Inherited from both parents (like most genetic diseases).

Why Is It Different in My Family Members?

Even if you and your sibling have the same mtDNA mutation, you might have different symptoms or severity. This is because of heteroplasmy—each cell has hundreds of mitochondria, some normal and some with mutations. The percentage of abnormal mitochondria determines how sick you are. Your sibling might have a different percentage, causing different symptoms.

Is There a Cure?

Currently, no cure exists for most mitochondrial diseases. Treatment focuses on:

• Managing symptoms: Medications for seizures, diabetes, heart problems, etc.
• Supporting energy production: Vitamins and supplements (CoQ10, riboflavin, carnitine)—these may help your mitochondria work a bit better.
• Preventing complications: Regular heart checks (pacemaker if needed), eye exams, hearing tests.
• Lifestyle: Avoid long fasting (eat regularly), gentle exercise, avoid smoking/alcohol (especially LHON).

For LHON, a medication called idebenone may help preserve or recover vision.

"Spoon Theory" and Energy Management

Imagine you wake up with a certain number of "energy spoons" each day. Every activity—getting dressed, cooking, walking—costs spoons. Once you're out of spoons, you're exhausted and need to rest. Unlike healthy people who can "borrow" spoons from tomorrow, you can't. Plan your day carefully: use spoons on what matters most, rest before you crash.

What Happens If I Get Sick?

Infections, fevers, and stress use lots of extra energy. Your body needs more mitochondria power to fight illness, but your mitochondria are already struggling. This can trigger a metabolic crisis (lactic acidosis, organ failure). Seek medical help early if you get sick. Drink sugary drinks (Lucozade, juice) to provide quick energy. Don't stop eating.

Can I Have Children?

If you have an mtDNA mutation (inherited from your mother):

• Women: You will pass the mutation to all children (sons and daughters). However, how much mutation they inherit is unpredictable (could be mild or severe).
• Men: You will not pass the mutation to children (fathers don't transmit mtDNA).

Options to prevent transmission:

• Egg donation: Use a donor's egg (donor's healthy mitochondria).
• Mitochondrial replacement therapy (MRT): "Three-parent IVF"—your nuclear DNA + donor's healthy mitochondria (legal in UK and Australia).

If you have a nuclear DNA mutation (autosomal recessive/dominant), genetic counseling can discuss recurrence risks and prenatal testing options.

Living with Mitochondrial Disease

• Pace yourself: Avoid overexertion. Rest before you're exhausted.
• Eat regularly: Small, frequent meals. Avoid fasting.
• Stay active: Gentle aerobic exercise (walking, swimming) may help your mitochondria work better. Avoid extreme exertion.
• Avoid triggers: Smoking, alcohol (especially LHON), prolonged fasting.
• Medication caution: Tell all doctors you have mitochondrial disease. Avoid valproate (epilepsy drug—toxic to mitochondria), avoid metformin (diabetes drug), avoid aminoglycosides (antibiotics like gentamicin).
• Support groups: Connect with others (Mito Foundation, United Mitochondrial Disease Foundation).

---

15. References

1. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:16080. doi:10.1038/nrdp.2016.80

2. Gorman GS, Schaefer AM, Ng Y, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77(5):753-759. doi:10.1002/ana.24362

3. Wen S, Deng F, Li L, et al. Mitochondrial diseases: from molecular mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025;10(1):12. doi:10.1038/s41392-024-02065-0

4. Hettiarachchi D, Lakmal K, Dissanayake VHW. Mitochondrial diseases in South Asia - A systematic review. Mitochondrion. 2022;62:1-19. doi:10.1016/j.mito.2021.10.005

5. Russell OM, Gorman GS, Lightowlers RN, Turnbull DM. Mitochondrial Diseases: Hope for the Future. Cell. 2020;181(1):168-188. doi:10.1016/j.cell.2020.02.051

6. Yu-Wai-Man P, Carelli V, Newman NJ, et al. Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial. Cell Rep Med. 2024;5(2):101403. doi:10.1016/j.xcrm.2024.101403

7. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015;116(1-2):4-12. doi:10.1016/j.ymgme.2015.06.004

8. Karaa A, Goldstein A. The spectrum of clinical presentation, diagnosis, and management of mitochondrial forms of diabetes. Pediatr Diabetes. 2015;16(1):1-9. doi:10.1111/pedi.12223

9. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet. 2015;16(9):530-542. doi:10.1038/nrg3966

10. Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. Kearns-Sayre syndrome: a case series of 35 adults and children. Int J Gen Med. 2014;7:325-332. doi:10.2147/IJGM.S65369

11. Ratnaike TE, Elkhateeb O, Lochmüller H, Horvath R. Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis. BMJ Neurol Open. 2024;6(1):e000646. doi:10.1136/bmjno-2024-000646

12. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30(2):81-114. doi:10.1016/j.preteyeres.2010.11.002

13. Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):124. doi:10.1038/s41392-024-01839-8

14. Jonckheere AI, Smeitink JA, Rodenburg RJ. Mitochondrial ATP synthase: architecture, function and pathology. J Inherit Metab Dis. 2012;35(2):211-225. doi:10.1007/s10545-011-9382-9

15. Balasubramaniam S, Christodoulou J, Rahman S. Disorders of riboflavin metabolism. J Inherit Metab Dis. 2019;42(4):608-619. doi:10.1002/jimd.12058

16. Dubowitz V, Sewry CA, Oldfors A. Muscle Biopsy: A Practical Approach. 4th ed. Saunders Elsevier; 2013.

17. Rahman S, Poulton J, Marchington D, Suomalainen A. Decrease of 3243 A→G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am J Hum Genet. 2001;68(1):238-240. doi:10.1086/316930

18. Cree LM, Samuels DC, de Sousa Lopes SC, et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet. 2008;40(2):249-254. doi:10.1038/ng.2007.63

19. Finsterer J, Zarrouk-Mahjoub S. Mitochondrial stroke-like episodes in MELAS. A systematic review. J Clin Neurosci. 2019;69:79-85. doi:10.1016/j.jocn.2019.08.002

20. Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. 2005;64(4):710-712. doi:10.1212/01.WNL.0000151976.60624.01

21. Lorenzoni PJ, Scola RH, Kay CS, et al. MERRF: Clinical features, muscle biopsy and molecular genetics in Brazilian patients. Mitochondrion. 2011;11(3):528-532. doi:10.1016/j.mito.2011.01.003

22. Harvey JN, Barnett D. Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol (Oxf). 1992;37(1):97-103. doi:10.1111/j.1365-2265.1992.tb02289.x

23. Rahman J, Noronha A, Thiele I, Rahman S. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol. 1996;39(3):343-351. doi:10.1002/ana.410390311

24. Carelli V, La Morgia C, Valentino ML, et al. Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders. Biochim Biophys Acta. 2009;1787(5):518-528. doi:10.1016/j.bbabio.2009.02.024

25. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011;134(Pt 9):2677-2686. doi:10.1093/brain/awr170

26. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet. 1993;4(3):289-294. doi:10.1038/ng0793-289

27. Rötig A, Bourgeron T, Chretien D, et al. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet. 1995;4(8):1327-1330. doi:10.1093/hmg/4.8.1327

28. Saneto RP, Friedman SD, Shaw DW. Neuroimaging of mitochondrial disease. Mitochondrion. 2008;8(5-6):396-413. doi:10.1016/j.mito.2008.05.003

29. McCormick EM, Lott MT, Dulik MC, et al. Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation. Hum Mutat. 2020;41(12):2028-2057. doi:10.1002/humu.24107

30. Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17(9):689-701. doi:10.1038/gim.2014.177

31. Koga Y, Povalko N, Nishioka J, Katayama K. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci. 2010;1201:104-110. doi:10.1111/j.1749-6632.2010.05624.x

32. Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev. 2008;60(13-14):1561-1567. doi:10.1016/j.addr.2008.05.001

33. Fontaine E. Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Front Endocrinol (Lausanne). 2018;9:753. doi:10.3389/fendo.2018.00753

34. Vanlander AV, Okun JG, de Jaeger A, et al. Possible pathogenic mechanism of propofol infusion syndrome involves coenzyme q. Anesthesiology. 2015;122(2):343-352. doi:10.1097/ALN.0000000000000484

35. Saneto RP, Lee IC, Koenig MK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure. 2010;19(3):140-146. doi:10.1016/j.seizure.2010.01.002

36. Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005;353(21):2305-2306. doi:10.1056/NEJM200511243532123

37. Farnezi HB, Goulart PFP, Santos AD, et al. Three-parent babies: Mitochondrial replacement therapies. JBRA Assist Reprod. 2020;24(2):189-196. doi:10.5935/1518-0557.20190091

38. Hyslop LA, Blakeley P, Craven L, et al. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature. 2016;534(7607):383-386. doi:10.1038/nature18303

39. Yu-Wai-Man P, Newman NJ, Carelli V, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020;12(573):eaaz7423. doi:10.1126/scitranslmed.aaz7423

40. Gammage PA, Moraes CT, Minczuk M. Mitochondrial genome engineering: the revolution may not be CRISPR-ized. Trends Genet. 2018;34(2):101-110. doi:10.1016/j.tig.2017.11.001

41. Janssen MCH, Koene S, de Laat P, et al. The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders. Clin Pharmacol Ther. 2019;105(1):101-111. doi:10.1002/cpt.1197

42. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12(5):763-771. doi:10.1111/acel.12102

43. Pirinen E, Auranen M, Khan NA, et al. Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. Cell Metab. 2020;32(1):144-156.e7. doi:10.1016/j.cmet.2020.05.020

44. Subramaniam T, Chirayath R, Iyer M, et al. Mesenchymal stem cells (MSCs) in Leber's hereditary optic neuropathy (LHON): a potential therapeutic approach for future. Int Ophthalmol. 2022;42(9):2923-2937. doi:10.1007/s10792-022-02290-y

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.